Peptides for mass applications

Exploit new market potentials

We enable high-potential peptide-based products to become applicable for mass markets.

Peptides for mass applications

Exploit new market potentials

We enable high-potential peptide-based products to become applicable for mass markets.

mk2 Biotechnologies develops, produces and investigates peptides using a revolutionary synthesis technology. Our innovative process allows the scalable and thus cost-efficient production of high-purity peptides for a broad range of applications.

Commercialize groundbreaking mass market products

Gain access to new and previously inaccessible long-chained peptides to develop new product IPs, improve existing products, and unlock new market potentials:

gears

R&D

Standards for analytics to enable fast, easy and high-quality research projects.

crop

Agriculture

Substitutes for fungicides, pesticides or fertilizers to enable sustainable plant breeding.

horse

Stock Breeding

Substitutes for antibiotics or growth hormones for products that enable sustainable animal breeding.

cosmetics

Cosmetics

Bioactive and natural ingredient and preservatives that enable novel personal care formulations.

food

Food & Beverage

Nutraceuticals, food & dietary supplements and growth factors for cultured meat to enable sustainable and affordable food production.

Pharmaceuticals

Pharmaceuticals

New active ingredients and treatment strategies to enable groundbreaking therapies and disease prevention.

mk2 News

Our latest news

mk2 Biotechnologies and Sartorius Stedim Biotech join forces to develop a biologics production platform
mk2 Biotechnologies and Sartorius Stedim Biotech join forces to develop a biologics production platform
28 June 2022
mk2 Biotechnologies, a peptide and protein production specialist for large-scale applications, and Sartorius Stedim Biotech Corporate Research, a leading technology and solutions provider to the biotech/biopharma industry, are happy to announce that they are joining forces to create the next-generation, low-cost biologics production platform. Integrating an intensified approach, the platform...
mk2 Biotechnologies, WACKER and TUM jointly develop a process for the large-scale production of antimicrobial peptides based on sustainable fermentation
mk2 Biotechnologies, WACKER and TUM jointly develop a process for the large-scale production of antimicrobial peptides based on sustainable fermentation
7 June 2022
Joint Press Release mk2 Biotechnologies, WACKER and TUM mk2 Biotechnologies, WACKER and the Technical University of Munich (TUM) today announced their joint project targeting the development, large-scale production and purification of antimicrobial peptides (AMPs) for diverse applications. The project will run for two years. The aim is to take the...
mk2 Biotechnologies Receives a Multi-Million Sum in Seed Funding
mk2 Biotechnologies Receives a Multi-Million Sum in Seed Funding
29 July 2021
Munich-based mk2 Biotechnologies today announced the receipt of several million Euros in seed funding to accelerate the further growth of the company. In particular, the company thrives to accomplish additional development milestones towards industrializing its novel peptide production platform. The financing round was led by OCCIDENT, with significant funds also...